Fig. 3

Sargramostim treatment stabilizes immunosuppressive surface markers of regulatory T cells. Quantification of a CD4⁺ lymphocytes, b CD4⁺ CD127highCD25⁺ Teffs, c CD4⁺ CD127lowCD25⁺ Tregs, d FOXP3⁺ Tregs, e CTLA⁺ Tregs, f ItgB7⁺ Tregs, g CD31⁺  Tregs, and h CD45RA-CD45RO⁺ Tregs over the course of treatment. Variables were measured at baseline (blue nodes), during drug treatment (green nodes), and during drug intermission (red nodes). Blue dashed lines indicate mean baseline measurement. Differences in means (± SEM) for each dependent variable grouped by time on treatment were determined by one-way ANOVA, and P values for multiple comparisons with baseline were adjusted by Dunnett's post-hoc test (marked by letter “a”) and by the method of Benjamini, Krieger and Yekutieli [36] for false discovery rate (FDR) (*) where P ≤ 0.05